Pediatric brain tumors such as high grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPGS) are still poorly understood. Researchers on this project are investigating whether pediatric HGGs and DIPGS display intratumoral genetic heterogeneity (an array of distinct tumor cells within a tumor type). Understanding the heterogeneity of a tumor is important to provide proper treatment. Researchers also hope to elucidate the relationship between genetic events and how they affect the origin and progression of HGGs and DIPGs. Some of the yet to be identified genetic combinations may alter responses to drugs, and researchers seek to further study ways to utilize such findings in the advancement of cancer therapies. Current findings from this research group are interesting, but their studies are severely underpowered without additional samples, making rare tissue and germline specimens provided by The Children’s Brain Tumor Network especially important to this project.
What are the goals of this project?
Researchers seek to better understand the genetic drivers of HGGs and DIPGs and how they evolve and progress.
What is the impact of this project?
A better understanding of tumor genetics is the first step to identifying new effective therapeutic strategies.
Why is the CBTN request important to this project?
The work being done on this project requires rare specimens unavailable nowhere but through the Children’s Brain Tumor Network.
The Children's Brain Tumor Tissue Consortium contributed to this project by providing germline and tissue samples.
University of Calgary
UCalgary is on a mission to discover new knowledge and translate our discoveries into applications that provide benefits to our communities. The University of Calgary is one of Canada’s top comprehensive research universities, with a mission to discover new knowledge and translate our discoveries
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test